ERBB2 and non-small cell lung carcinoma: As a member of the ERBB receptor family, HER2 alterations are involved in the oncogenic process in a variety of solid tumors, mainly including HER2 mutation, HER2 amplification, and HER2 overexpression, with corresponding incidence rates of 1%-6.7%, 2%-22%, and 7.7%-23%, respectively, in NSCLC and all of them are associated with poor prognosis (52–55).